Samsung Biologics, the biotech arm of Samsung Group, said Monday that it will participate in the JP Morgan Healthcare Conference, the world’s largest healthcare investment symposium, next week.

Now in its 43rd year, the JPMHC is held every January in San Francisco, California. The event, scheduled for Monday through Thursday next week, is expected to draw 550 biotech companies and over 8,000 attendees.

Among the invited companies, only 27 were selected to present at the Grand Ballroom in the Westin St. Francis. The presentation order is determined based on each company’s industry presence.

Samsung Biologics has been invited to speak at the conference for nine consecutive years since 2017. Since last year, the company is assigned on the second day, alongside other big pharma leaders such as GlaxoSmithKline, Eli Lilly and AstraZeneca.

CEO John Rim will deliver a presentation under the theme “4E,” which highlights the company’s focus on customer excellence, operational excellence, quality excellence and people excellence. Rim will outline its consistent growth since his appointment and discuss the business strategy for this year.

Samsung Biologics reported record-breaking achievements last year, surpassing 5 trillion won ($3.4 billion) in cumulative annual order values. “Rim’s extensive experience with leading pharmaceutical firms, including Genentech, Roche and Astellas Pharma, has been crucial in driving this success,” said a company official.

By actively engaging with investors and potential clients, Samsung aims to strengthen its position in the global contract development and manufacturing organization market and further expand its business network.

By Park Min-ha (en23mp@heraldcorp.com)